G1 Treatment (NASDAQ:GTHX) on Wednesday said that phase 2 showed the ability of trilaciclib to reduce adverse events (AEs) associated with an antibody-mediated drug (ADC).
The company reported preliminary safety data from the first 18 enrollees an ongoing trial 2 of trilaciclib administered before the ADC sacituzumab govitecan-hziy, sold as Trodelvy by Gilead (NASDAQ:GILD), in patients with unresectable advanced or metastatic triple-negative breast cancer (TNBC).
G1 added that trilaciclib was well tolerated when administered before sacituzumab.
The data showed that an effective trial on trilaciclib reduces (> 50%) the rate of major complications compared to a data previously published in Trodelvy from the ASCENT study. These events include myelosuppression (neutropenia, anemia, thrombocytopenia), and diarrhea and possibly alopecia due to the presence of CDK4/6-expressing cells in the intestinal crypt and hair follicles, approximately with the company.
“We believe that we are seeing the effects of trilaciclib in the expected reduction of the rate of myelosuppression and the rate of diarrhea and possible alopecia,” said G1 Chief Medical Officer Raj Malik.
G1 stated that the main objective of the study was to evaluate the anti-tumor efficacy of trilaciclib when administered before Trodelvy as measured by progression-free survival.
GTHX +5.87% at $11.55 premarket Nov